Symyx Launches Contract Development and Manufacturing Organization for Biopharmaceuticals
News Apr 23, 2009
Symyx Technologies, Inc. has announced the launch of the Symyx Contract Development and Manufacturing Organization (CDMO). The Symyx CDMO helps biopharmaceutical companies move promising drug candidates to clinical trials faster and reliably with integrated formulation development, and preclinical and CGMP fill/finish manufacturing.
"After discovery, the next critical milestone in drug development is getting to clinical trials quickly with a reliable formulation. The Symyx CDMO provides clients a faster, more reliable route to clinical trials," said Richard Boehner, president of Symyx High Productivity Research (HPR). “We do this by combining unsurpassed formulation expertise, high-productivity research technology and CGMP clinical manufacturing in a single facility."
With expertise in preformulation development, formulation optimization and stability, and analytical method development, the Symyx CDMO enables development of highly optimized and robust drug formulations, so that clinical trials test the efficacy of drug candidates, not the limitations of the formulation.
In addition, the Symyx CDMO offers full service fill/finish execution for delivering drug products manufactured under CGMP conditions while maintaining the integrity of drug substances and meeting preclinical and Phase I and II clinical trial schedules.
Researchers Develop Novel ‘One-pot’ Approach to Conjugated Tetraenes SynthesisNews
TUAT researchers have achieved the new synthetic route of conjugated tetraenes from inexpensive and easily available 1,3-butadiene and substituted acetylenes by a one-pot approach under mild conditions. Conjugated tetraenes are important key substructures in biologically active natural products such as vitamins, and anti-mycotic drugs.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE